Telo Genomics Corp. announced that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma (MM) clinician, key opinion leader and medical diagnostics expert to establish and chair company's MM clinical advisory board (Advisory Board). Dr. Bender is a board-certified oncologist who brings more than 40 years of experience in hematological
malignancy with a special focus on MM. He received his medical degree from the UCLA School of Medicine and completed his internship and residency at UCLA-Harbor General Hospital followed by a hematology/oncology fellowship at the National Cancer Institute. His past titles include Medical Director for Hematology/Oncology for Quest Diagnostics, Medical Director for Hematology/Oncology for Kaiser Permanente in San Diego, and Chief Medical Officer for both Agendia and Signal Genetics. Dr. Bender has also served on the executive board of the San Diego Hospice and American Cancer Society and has been retained by the FDA as a member of the Hematology and Pathology Devices Advisory Committee. He continues to teach at the UCLA School of Medicine and has authored more than 80 peer-reviewed scientific articles and book chapters.